Fatigue

===Medications to treat fatigue===
The UK [[National Institute for Health and Care Excellence|NICE]] recommends consideration of amantadine, modafinil and SSRIs for MS fatigue.<ref>{{Cite web|url=https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#ms-symptom-management-and-rehabilitation|title=Recommendations &#124; Multiple sclerosis in adults: management &#124; Guidance &#124; NICE|date=June 22, 2022|website=www.nice.org.uk|access-date=January 7, 2023|archive-date=January 7, 2023|archive-url=https://web.archive.org/web/20230107085547/https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#ms-symptom-management-and-rehabilitation|url-status=live}}</ref> [[Psychostimulant]]s such as [[methylphenidate]], [[amphetamine-type stimulant|amphetamine]]s, and [[modafinil]] have been used in the treatment of fatigue related to [[depression (mood)|depression]],<ref name="pmid18425966">{{cite journal |vauthors=Candy M, Jones L, Williams R, Tookman A, King M |title=Psychostimulants for depression |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD006722 |date=April 2008 |pmid=18425966 |doi=10.1002/14651858.CD006722.pub2 |url= }}</ref><ref name="pmid19281939">{{cite journal |vauthors=Hardy SE |title=Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults |journal=Am J Geriatr Pharmacother |volume=7 |issue=1 |pages=34–59 |date=February 2009 |pmid=19281939 |pmc=2738590 |doi=10.1016/j.amjopharm.2009.02.006 |url= }}</ref><ref name="pmid26906078">{{cite journal |vauthors=Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, Mulder R, Porter R, Singh A, Murray G |title=Stimulants for depression: On the up and up? |journal=Aust N Z J Psychiatry |volume=50 |issue=3 |pages=203–207 |date=March 2016 |pmid=26906078 |doi=10.1177/0004867416634208 |s2cid=45341424 |url= }}</ref><ref name="pmid34144366">{{cite journal |vauthors=Bahji A, Mesbah-Oskui L |title=Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis |journal=J Affect Disord |volume=292 |issue= |pages=416–423 |date=September 2021 |pmid=34144366 |doi=10.1016/j.jad.2021.05.119 |url= }}</ref> and [[medical illness]] such as [[chronic fatigue syndrome]]<ref name="pmid20088743">{{cite journal |vauthors=Van Houdenhove B, Pae CU, Luyten P |title=Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy? |journal=Expert Opin Pharmacother |volume=11 |issue=2 |pages=215–223 |date=February 2010 |pmid=20088743 |doi=10.1517/14656560903487744 |s2cid=34827174 |url= }}</ref><ref name="pmid18505357">{{cite journal |vauthors=Valdizán Usón JR, Idiazábal Alecha MA |title=Diagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate |journal=Expert Rev Neurother |volume=8 |issue=6 |pages=917–927 |date=June 2008 |pmid=18505357 |doi=10.1586/14737175.8.6.917 |s2cid=37482754 |url= }}</ref> and [[cancer]].<ref name="pmid19281939" /><ref name="pmid8856815">{{cite journal |vauthors=Masand PS, Tesar GE |title=Use of stimulants in the medically ill |journal=Psychiatr Clin North Am |volume=19 |issue=3 |pages=515–547 |date=September 1996 |pmid=8856815 |doi=10.1016/s0193-953x(05)70304-x |url= }}</ref><ref name="pmid20870637">{{cite journal |vauthors=Breitbart W, Alici Y |title=Psychostimulants for cancer-related fatigue |journal=J Natl Compr Canc Netw |volume=8 |issue=8 |pages=933–942 |date=August 2010 |pmid=20870637 |doi=10.6004/jnccn.2010.0068 |url= |doi-access=free}}</ref><ref name="pmid21251796">{{cite journal |vauthors=Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC |title=Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis |journal=J Pain Symptom Manage |volume=41 |issue=4 |pages=761–767 |date=April 2011 |pmid=21251796 |doi=10.1016/j.jpainsymman.2010.06.020 |url= |doi-access=free}}</ref><ref name="pmid24416225">{{cite journal |vauthors=Gong S, Sheng P, Jin H, He H, Qi E, Chen W, Dong Y, Hou L |title=Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis |journal=PLOS ONE |volume=9 |issue=1 |pages=e84391 |date=2014 |pmid=24416225 |pmc=3885551 |doi=10.1371/journal.pone.0084391 |bibcode=2014PLoSO...984391G |url= |doi-access=free}}</ref><ref name="pmid25299141">{{cite journal |vauthors=Yennurajalingam S, Bruera E |title=Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids |journal=Cancer J |volume=20 |issue=5 |pages=319–324 |date=2014 |pmid=25299141 |doi=10.1097/PPO.0000000000000069 |s2cid=29351114 |url= }}</ref><ref name="pmid25814977">{{cite journal |vauthors=Dobryakova E, Genova HM, DeLuca J, Wylie GR |title=The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders |journal=Front Neurol |volume=6 |issue= |page=52 |date=2015 |pmid=25814977 |pmc=4357260 |doi=10.3389/fneur.2015.00052 |url= |doi-access=free}}</ref> They have also been used to counteract fatigue in [[sleep loss]]<ref name="pmid16268386">{{cite journal |vauthors=Bonnet MH, Balkin TJ, Dinges DF, Roehrs T, Rogers NL, Wesensten NJ |title=The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine |journal=Sleep |volume=28 |issue=9 |pages=1163–1187 |date=September 2005 |pmid=16268386 |doi=10.1093/sleep/28.9.1163 |url= |doi-access=free}}</ref> and in [[aviation]].<ref name="pmid33754977">{{cite journal |vauthors=Ehlert AM, Wilson PB |title=Stimulant Use as a Fatigue Countermeasure in Aviation |journal=Aerosp Med Hum Perform |volume=92 |issue=3 |pages=190–200 |date=March 2021 |pmid=33754977 |doi=10.3357/AMHP.5716.2021 |s2cid=232325161 |url= }}</ref>